Study Urges Caution Before Adopting ICER Reviews to Determine Cost Effectiveness of Treatments

Share on Facebook
Share on Twitter
Share on
LinkedIn
+

Review methodology could negatively impact elderly, the disabled, cancer patients and those with rare diseases

Media inquiries: Contact Micaela Dawson, 617-723-2277 ext. 203 or mdawson@pioneerinstitute.org

BOSTON – As states continue to grapple with prescription drug costs, a new Pioneer Institute study lays out the key ethical, methodological and disease-specific questions policy makers should address before deciding whether to contract with the Institute for Clinical and Economic Review (ICER) to conduct cost effectiveness reviews used to make decisions about the purchase of medicines and other medical innovations.

ICER utilizes Quality Adjusted Life Years (QALYs), a controversial evaluation technique that assigns an economic value to the longevity and quality of human life.

“The use of the QALY standard in the United Kingdom resulted in British cancer patients having some of the worst access to new cancer treatments in all of Europe and created a political crisis for British politicians,” said William Smith, author of “Key Questions for Legislators on the Institute for Clinical and Economic Review (ICER).” “U.S. politicians may want to proceed cautiously in adopting QALYs.”

QALY is controversial because of the impact that such a methodology may have upon access to medical innovations for older Americans, the disabled, patients with cancer and patients with rare diseases.

The National Health Service (NHS) in the United Kingdom utilizes QALY metrics.  But in the United States, the Affordable Care Act banned the use of QALYs for Medicare programs because of concerns about the impact upon older Americans, the disabled and the terminally ill.

Because of the vulnerability of these patient populations, Pioneer recommends that legislators avoid using ICER reviews until they are fully confident that the reviews will neither have an adverse impact upon these vulnerable populations nor discourage biopharmaceutical innovation for important unmet medical needs.

Download our one-page summary, Key Questions for Legislators.”

About the Author

William S. Smith is Visiting Fellow in Life Sciences at Pioneer Institute.  He has 25 years of experience in government and in corporate roles, including as vice president of public affairs and policy at Pfizer, and as a consultant to major pharmaceutical, biotechnology and medical device companies. He held senior staff positions for the Republican House leadership on Capitol Hill, the White House, and in the Massachusetts Governor’s office. He is affiliated as research fellow and managing director with the Center for the Study of Statesmanship at The Catholic University of America (CUA), where he earned his PhD.

About Pioneer

Pioneer Institute is an independent, non-partisan, privately funded research organization that seeks to improve the quality of life in Massachusetts through civic discourse and intellectually rigorous, data-driven public policy solutions based on free market principles, individual liberty and responsibility, and the ideal of effective, limited and accountable government.

Get Updates On Our Healthcare Research and Events!

Make a tax-deductible gift below to support our work to protect patients.

Related Posts:

Pioneer Forming Transparency Working Group to Help Curb Healthcare Costs

Contact Josh Archambault (617) 645-7679 (josh@pioneerinstitute.org)…

Study: Are Drug Prices Driving Healthcare Cost Growth?

Study: Requiring Drug Companies to Disclose Price Methodologies,…

Study: Health Care Costs on Course to Threaten Livelihood of Most American Families

/
Read news coverage of this report in the Springfield Republican. Percentage…

Mass. Healthcare Price Transparency Law Still Not a Reality

State Healthcare Price Transparency Law Still Not a Reality for…

Survey: Price Information Difficult to Obtain From Massachusetts Hospitals

View media coverage of this report on WCVB-TV 5 Investigates:…

Press Release: Whistleblowers’ Behind-the-Scenes Account of Health Connector Meltdown

UPDATE: Read news coverage of this report in The Wall Street…

Barbara Anthony Joins Pioneer Institute as Senior Fellow in Healthcare

Former undersecretary of consumer affairs will work to enhance…

Baker’s Dozen: A Common Sense Healthcare Agenda for the Next Governor

/
Pioneer Institute is pleased to present, “Baker’s Dozen:…

Study: $1B Price Tag for ACA Health Exchange & New Medicaid Program in Mass.

Study: $1 Billion Price Tag for ACA Health Exchange & New…

Study: Reduce Privacy Leaks to Achieve Full Potential of Electronic Health Records

Press Release: Study Finds That Focus on Reducing Privacy Leaks…

Why Boston’s Ban on Convenient Care Clinics Is Costing Taxpayers Millions

Study Urges Boston Mayoral Candidates to Reverse City Policy,…

Archambault to Become Pioneer Senior Fellow, Work on Medicaid Reform Outside MA

Archambault to Become Senior Fellow at Pioneer Institute and…

ACA Medicare Payroll Tax Costs MA $1.7B Over 10 Years; 3 Patriots to Pay $707,850 in 2013

ACA also includes additional 3.8% Medicare tax on net investment…

New Report: Medical Device Tax Will Cost MA Employers $422 Million+ Per Year

New Report Estimates Medical Device Tax Will Cost Massachusetts…

Pioneer Requests Report That Predicts ACA’s “Extreme Premium Increases”

/
Pioneer Files Request for the Administration to Release Its Report…

Consumer Driven Health Care a Proven Cost-Saving Strategy

/
As part of a push to contain health care cost growth, business leaders, state administrators, and policymakers should focus on Consumer Driven Health Care (CDHC) plans that involve consumers in making health care decisions.

Big “Cadillac Tax” Ahead for Massachusetts’ Middle Class

A new brief from Pioneer Institute, The Impact of the Federal Health Law’s “Cadillac Insurance Tax” in Massachusetts, estimates additional costs associated with the ACA's so-called "Cadillac tax," will affect well over 50% of workers in Massachusetts.